Western genetic medicine makers turn to Chinese investigator-initiated trials
西方基因药企转向manbetx3.0 的研究者发起临床试验

Earlier this year, the Belgian cell therapy startup EsoBiotec had only 12 employees and had raised €22 million to develop a cutting-edge infusion that turns a patient’s immune cells into destroyers of disease.
今年早些时候，比利时细胞治疗初创公司EsoBiotec只有12名员工，并已筹集2200万欧元，用于开发一款最前沿的输注疗法，可将患者的免疫细胞转化为疾病清除者。